* Q4 loss/shr $0.09 vs est loss/shr $0.13
* Q4 rev $20.7 mln vs est $21.4 mln
* Shares up 9 pct after market
Aug 13 (Reuters) – Array BioPharma Inc posted a
lower-than-expected quarterly loss as operating expenses fell,
sending its shares up as much as 9 percent after the bell.
Fourth-quarter net loss narrowed to $8 million, or 9 cents
per share, from $21.8 million, or 38 cents per share, a year
earlier.
Revenue rose about 9 percent to $20.7 million. Total
operating expenses fell 18 percent to $25.6 million.
Analysts on average had expected a loss of 13 cents per
share, on revenue of $21.4 million, according to Thomson Reuters
I/B/E/S.
The company said in July that its experimental pain drug did
not reduce pain better than the existing standard of care in a
mid-stage study.
Shares of the Boulder, Colorado-based company, which have
risen about 31 percent in the last three months, were up 9
percent after the bell. They had closed at $4.56 on Monday on
the Nasdaq.
(Reporting by Balaji Sridharan in Bangalore; Editing by Supriya
Kurane)
